Myeloma articles within Nature

Featured

  • Article |

    The crystal structures of thalidomide and its derivatives bound to the E3 ligase subcomplex DDB1–CRBN are shown; these drugs are found to have dual functions, interfering with the binding of certain cellular substrates to the E3 ligase but promoting the binding of others, thereby modulating the degradation of cellular proteins.

    • Eric S. Fischer
    • , Kerstin Böhm
    •  & Nicolas H. Thomä

  • Outlook |

    Unlocking the genetic secrets of multiple myeloma could reveal new ways to attack this killer disease.

    • Courtney Humphries

  • Outlook |

    Identifying the patients most likely to progress from a precancerous condition to multiple myeloma could help doctors catch the disease early and stop it taking hold.

    • Lauren Gravitz

  • Outlook |

    Despite its rarity, multiple myeloma is an ideal testing ground for cancer biology, says William Matsui.

    • William Matsui

  • Outlook |

    Drugs introduced to fight multiple myeloma in the past decade have revolutionized treatment and extended patients' lives. Are the improvements set to continue?

    • Adrianne Appel

  • Outlook |

    In the fight against myeloma, researchers are investigating its interactions with molecular neighbours in the bone marrow.

    • Virginia Hughes

  • Outlook |

    New technology to peer into the bones could help improve the treatment of multiple myeloma patients.

    • Cassandra Willyard

  • Outlook |

    Multiple myeloma begins with a benign condition before progression to full-blown cancer, and work is underway to uncover the origins of both.

    • Cynthia Graber

  • Outlook |

    Finding a treatment for the bone destruction caused by myeloma helped researchers understand the biology of bone.

    • Jennifer Berglund

  • Outlook |

    Stem-cell transplants are an important tool for treating myeloma. But with improved drug alternatives, doctors disagree about the best time to give the treatment.

    • Elie Dolgin

  • Article
    | Open Access

    Multiple myeloma, a malignancy of plasma cells, remains incurable and is poorly understood. Using next-generation sequencing of several multiple myeloma genomes reveals that this disease involves mutations of genes involved in protein translation, histone methylation and blood coagulation. The study suggests that BRAF inhibitors should be evaluated in multiple myeloma clinical trials.

    • Michael A. Chapman
    • , Michael S. Lawrence
    •  & Todd R. Golub

  • Letter |

    Recruitment of 53BP1 to double-strand DNA breaks is an important step in the cellular response to DNA damage. Here, the histone methyltransferase MMSET is shown to be responsible for localized increases in a histone modification that is involved in recruiting 53BP1. The mechanism of MMSET recruitment to DNA damage sites is also investigated.

    • Huadong Pei
    • , Lindsey Zhang
    •  & Zhenkun Lou

Browse broader subjects

Browse Myeloma across other nature.com journals